Skip to main content

KILL New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 

Genentech requests that their press release NewsItemId: 20240125093104 “New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)” be killed.

The release was issued prematurely by Genentech.

A replacement release will be issued at a later date.

Contacts

Media Contact:

Shirley Dang, (650) 467-6800

Advocacy Contact:

Danielle Haney, (240) 805-4810

Investor Contacts:

Loren Kalm, (650) 225-3217

Bruno Eschli, +41 61 687 5284

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  251.89
-0.51 (-0.20%)
AAPL  326.57
+11.23 (3.56%)
AMD  503.60
-17.50 (-3.36%)
BAC  62.56
-0.11 (-0.18%)
GOOG  330.39
+2.01 (0.61%)
META  644.38
-9.31 (-1.42%)
MSFT  492.44
+0.79 (0.16%)
NVDA  218.36
-5.31 (-2.37%)
ORCL  152.94
-8.69 (-5.38%)
TSLA  363.56
-4.25 (-1.16%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.